Relmada Therapeutics to Discuss Q3 Financial Results
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering clinical-stage biotechnology company, is gearing up to share important financial outcomes during a conference call and webcast. This event is scheduled for Thursday, November 13, 2025, starting at 4:30 PM ET, where the team will address their financial performance for the third quarter ending September 30, 2025, alongside current advancements in their business initiatives.
Event Schedule and Participation Details
During the call, investors and stakeholders can expect detailed insights into Relmada's financial performance and growth trajectory. To ensure full accessibility, here are the participation details:
- Date: Thursday, November 13, 2025, at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Webcast Access: Available through the Investors section of the Relmada website.
A recording of the webcast will also be available for future access, allowing those unable to join live to still benefit from the discussion.
About Relmada Therapeutics
Relmada Therapeutics is devoted to crafting groundbreaking therapies aimed at addressing significant health challenges, particularly in oncology and central nervous system disorders. The company's promising candidates, NDV-01 and sepranolone, are currently in mid-stage clinical trials and promise to usher in new treatments where options are limited.
Connect with Relmada Therapeutics
Investors and the public can remain informed about Relmada's progress and news updates through its official website, which offers a wealth of information on ongoing projects and future directions.
Investor Relations and Media Contacts
For those seeking to engage further with Relmada, the following contacts are available:
Investor Contact:
Brian Ritchie
LifeSci Advisors
Email: britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
Email: media@relmada.com
Frequently Asked Questions
What is the purpose of the conference call being hosted by Relmada Therapeutics?
The purpose of the conference call is to discuss the financial results for the third quarter and provide updates on the company's recent business developments.
When will the Relmada Therapeutics conference call take place?
The conference call is scheduled for Thursday, November 13, 2025, at 4:30 PM ET.
How can investors listen to the conference call?
Investors can listen to the conference call by dialing in using the specified participant numbers or by accessing the webcast available on the Relmada website.
What are the two lead candidates being developed by Relmada Therapeutics?
Relmada's lead candidates are NDV-01 and sepranolone, which are in mid-stage clinical development for various health conditions.
Who should I contact for investor relations inquiries regarding Relmada Therapeutics?
For investor relations inquiries, you can contact Brian Ritchie at LifeSci Advisors via the provided email.